Adeona Pharmaceuticals, Inc. (AEN), a development-stage, specialty pharmaceutical company, has dedicated its efforts to developing proprietary, late-stage drug candidates designed to treat autoimmune and central nervous system (CNS) diseases. The company’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have proven clinical efficacy for the treatment medical diseases that are as of yet unattended to. For further information, visit the Company’s web site at www.adeonapharma.com.
- 17 years ago
QualityStocks
Adeona Pharmaceuticals, Inc. AEN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Adageis Brings Key Advantages in Pivot to Value-Based Healthcare
Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward…
-
QualityStocksNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Advancing Strategic Path in Resurging Market
Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is well positioned as platinum and palladium prices…
-
QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Sees 245% Surge in Juve Stabia Valuation Following Promotion Playoff Run
Brera Holdings (NASDAQ: BREA), an Ireland-based company executing a multi-club ownership strategy in global football,…